Outlook Therapeutics Inc (OTLK)

[H2R]

Cantor Global Healthcare Conference
September 26, 2023 1:35 p.m. ET11'30

A couple of notes. Nothing earth-shattering.

https://ir.outlooktherapeutics.com/news-releases/news-release-details/outlook-therapeuticsr-present-2023-cantor-fitzgerald-global
See the live video link

11'30'' Currently, pricing and efficacy lead to about 50% of the market to repackaged bevacizumab.

14' In the trial, Russ talks about the one -one! - minor safety concern, treated and resolved. Excellent safety profile.

15'30'' As long as you make ONS5010 is within reach. Asked payors, doctors what pricing ought to be. ONS-5010 pricing should be in line with the response OTLK received.

16'34'' OTLK will provide a briefing document to the FDA to address and at the same time will request an FDA meeting.
The FDA has 30 days to meet once the request is issued.
Unclear as to the request date. "Soon" is not precise.
Anyways, just a couple of notes.

Best of luck with your investments